Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis

BACKGROUND: Controlled and real-world evidence have demonstrated the efficacy of calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine. However, data on the over-one-year sustained effectiveness of CGRP MABs in resistant chronic migraine (CM) is sparse.  METHODS: This is a...

Descripción completa

Detalles Bibliográficos
Autores principales: Andreou, Anna P., Fuccaro, Matteo, Hill, Bethany, Murphy, Madeleine, Caponnetto, Valeria, Kilner, Rachael, Lambru, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635079/
https://www.ncbi.nlm.nih.gov/pubmed/36333710
http://dx.doi.org/10.1186/s10194-022-01507-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635079/
https://www.ncbi.nlm.nih.gov/pubmed/36333710
http://dx.doi.org/10.1186/s10194-022-01507-8

Ejemplares similares